NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisals No.249: Dabigatran etexilate for the prevention of stroke in atrial fibrillation, and No.256; Rivaroxaban for the prevention of stroke in atrial fibrillation

Provisional matrix of consultees and commentators

<table>
<thead>
<tr>
<th>Consultees</th>
<th>Commentators (no right to submit or appeal)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturers/sponsors</strong></td>
<td>General</td>
</tr>
<tr>
<td>• Bayer (rivaroxaban)</td>
<td>• Allied Health Professionals Federation</td>
</tr>
<tr>
<td>• Boehringer Ingelheim (dabigatran etexilate)</td>
<td>• Board of Community Health Councils in Wales</td>
</tr>
<tr>
<td><strong>Patient/carer groups</strong></td>
<td>• British Cardiovascular Industry Association</td>
</tr>
<tr>
<td>• Action Heart</td>
<td>• British National Formulary</td>
</tr>
<tr>
<td>• Afya Trust</td>
<td>• Care Quality Commission</td>
</tr>
<tr>
<td>• AntiCoagulation Europe</td>
<td>• Commissioning Support Appraisals Service</td>
</tr>
<tr>
<td>• Arrhythmia Alliance</td>
<td>• Department of Health, Social Services and Public Safety for Northern Ireland</td>
</tr>
<tr>
<td>• Atrial Fibrillation Association</td>
<td>• Healthcare Improvement Scotland</td>
</tr>
<tr>
<td>• Black Health Agency</td>
<td>• Medicines and Healthcare Products Regulatory Agency</td>
</tr>
<tr>
<td>• Blood Pressure Association</td>
<td>• National Association of Primary Care</td>
</tr>
<tr>
<td>• British Cardiac Patients Association</td>
<td>• National Pharmacy Association</td>
</tr>
<tr>
<td>• Counsel and Care</td>
<td>• NHS Alliance</td>
</tr>
<tr>
<td>• Different Strokes</td>
<td>• NHS Commercial Medicines Unit</td>
</tr>
<tr>
<td>• Equalities National Council</td>
<td>• NHS Confederation</td>
</tr>
<tr>
<td>• Heart Care Partnership</td>
<td>• Public Health Wales NHS Trust</td>
</tr>
<tr>
<td>• HEART UK</td>
<td>• Scottish Medicines Consortium</td>
</tr>
<tr>
<td>• Muslim Council of Britain</td>
<td></td>
</tr>
<tr>
<td>• Muslim Health Network</td>
<td></td>
</tr>
<tr>
<td>• Network of Sikh Organisations</td>
<td></td>
</tr>
<tr>
<td>• South Asian Health Foundation</td>
<td></td>
</tr>
<tr>
<td>• Specialised Healthcare Alliance</td>
<td></td>
</tr>
<tr>
<td>• The Somerville Foundation (formerly known as Grown Up Congenital Heart Patients Association)</td>
<td></td>
</tr>
<tr>
<td>• The Stroke Association</td>
<td></td>
</tr>
<tr>
<td><strong>Professional groups</strong></td>
<td>Possible Comparator manufacturer(s)</td>
</tr>
<tr>
<td>• Anticoagulation Specialist Association</td>
<td>• Actavis UK (aspirin)</td>
</tr>
<tr>
<td>• British Association for Nursing in Cardiovascular Care</td>
<td>• Alliance Pharma (aspirin)</td>
</tr>
<tr>
<td>• British Association for Service to the</td>
<td>• Aspar Pharmaceuticals (aspirin)</td>
</tr>
</tbody>
</table>

National Institute for Health and Clinical Excellence
NICE Technology Appraisal Nos. 249/256; Dabigatran etexilate and rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Issue date: November 2012
### Consultees

- Elderly
  - British Association of Stroke Physicians
  - British Atherosclerosis Society
  - British Cardiovascular Intervention Society
  - British Cardiovascular Society
  - British Geriatrics Society
  - British Heart Foundation
  - British Nuclear Cardiology Society
  - British Society for Haemostasis and Thrombosis
  - British Society for Heart Failure
  - British Society of Cardiovascular Imaging
  - Clinical Leaders of Thrombosis
  - Heart Rhythm UK
  - National Heart Forum (UK)
  - Primary Care Cardiovascular Society
  - Royal College of General Practitioners
  - Royal College of Nursing
  - Royal College of Pathologists
  - Royal College of Physicians
  - Royal Pharmaceutical Society
  - Royal Society of Medicine
  - Society for Cardiological Science and Technology
  - Society for Vascular Technology
  - Society of Vascular Nurses
  - The British Society for Haematology
  - United Kingdom Clinical Pharmacy Association
  - Vascular Society

- Others
  - Arden PCT Cluster
  - Birmingham and Solihull PCT Cluster
  - Department of Health
  - Welsh Government

### Commentators (no right to submit or appeal)

- Genus Pharmaceuticals (aspirin)
- Mercury Pharma (warfarin)
- Rosemont Pharmaceuticals (warfarin)
- Sandoz (aspirin, warfarin)
- Taro Pharmaceuticals (warfarin)
- Teva UK (aspirin, warfarin)
- Thornton & Ross (aspirin)
- Wockhardt UK (aspirin)
- Zentiva UK (warfarin, aspirin)

### Relevant research groups

- Antithrombotic Trialists’ Collaboration
- British Society for Cardiovascular Research
- Cardiac and Cardiology Research Dept, Barts
- Central Cardiac Audit Database
- Cochrane Heart Group
- Cochrane Stroke Group
- CORDA
- European Council for Cardiovascular Research
- MRC Clinical Trials Unit
- National Heart Research Fund
- National Institute for Health Research
- Research Institute for the Care of Older People
- Wellcome Trust - Cardiovascular Research Initiative

### Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

### Associated Guideline Groups

- National Clinical Guideline Centre

### Associated Public Health Groups

- None

---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.
PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS
Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.